Kissei's overactive bladder drug fails Phase III trial
This article was originally published in Scrip
Executive Summary
The future of a novel overactive bladder (OAB) drug being developed by the mid-sized Japanese firm Kissei has been thrown into doubt after the molecule missed its primary endpoint in a Phase III clinical study.